Uses of diosmetin or a pharmaceutically acceptable derivative thereof in the preparation of a medicament for alleviating, preventing or delaying alzheimer's disease (AD) in a subject

HK30136967AActive Publication Date: 2026-08-28HONG KONG BAPTIST UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK32026122908
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2026-04-17
Filing Date
2026-05-05
Publication Date
2026-08-28

Smart Images

  • Figure 00000029_0000
    Figure 00000029_0000
  • Figure 00000029_0001
    Figure 00000029_0001
  • Figure 00000030_0000
    Figure 00000030_0000
Patent Text Reader

Abstract

This invention relates to a pharmaceutical composition for the prevention and treatment of Alzheimer's disease (AD), the pharmaceutical composition comprising an effective amount of diosmetin. The invention also relates to the use of diosmetin or a pharmaceutically acceptable derivative thereof in the preparation of a medicament for alleviating, preventing, or delaying AD in an individual, wherein the preventive and therapeutic effects are achieved by promoting autophagy, which is activated via an autolysosomal pathway mediated by at least one of transcription factor EB (TFEB) and transcription factor E3 (TFE3); wherein the activation is achieved by promoting the dephosphorylation of at least one of TFEB and TFE3.
Need to check novelty before this filing date? Find Prior Art

Description

1. Use of Diosmetin or a pharmaceutically acceptable derivative thereof in the preparation of a medicament for alleviating, preventing, or delaying Alzheimer's disease (AD) in an individual. Technical Field This invention relates to a pharmaceutical composition for the prevention and treatment of Alzheimer's disease (AD) and the use of diosmetin or a pharmaceutically acceptable derivative thereof in the preparation of a medicament for alleviating, reducing, preventing, or delaying AD in a subject, by administering an effective amount of diosmetin to a subject in need to regulate the autolysosomal pathway mediated by transcription factor EB (TFEB) and transcription factor E3 (TFE3), wherein this regulation is achieved by promoting the dephosphorylation of at least one of TFEB and TFE3. Background Art AD is the most prevalent neurodegenerative disease worldwide, with a prevalence of approximately 10% in people over 65 years of age and rising to 32% in people over 85 years of age. According to the "China Alzheimer's Disease Report 2024," there are currently 16,990,827 people in China suffering from Alzheimer's disease (AD) and other dementias. With changing lifestyles and an aging population, the incidence of AD is rising year by year, placing a huge burden on families and society. The pathogenesis of AD is extremely complex. Currently, most clinical drugs target β-amyloid beta (Aβ) deposition or abnormal phosphorylation of Tau protein, but these treatments only temporarily relieve symptoms and are often accompanied by various adverse reactions or fail to achieve the expected clinical effects. Therefore, finding anti-AD drugs that act on novel targets is of significant clinical importance. This invention addresses this unmet clinical need by exploring new molecular mechanisms and therapeutic pathways—especially the regulation of autophagy and neuroinflammation—to provide more effective and safer new strategies for the prevention and treatment of AD. Neuroinflammation has attracted increasing attention in the pathogenesis of AD. Nucleotide HK 30136967 A 2 binds to NOD-like receptor protein 3 (NLRP3). Inflammasome-mediated neuroinflammation plays a crucial role in the pathogenesis of Alzheimer's disease (AD). In microglia of AD patient brain tissue, levels of NLRP3 inflammasome activation products pro-caspase-1 (Pro Caspase-1) and mature interleukin-1β (IL-1β) are significantly elevated. Autophagy can inhibit NLRP3 inflammasome activation, TFEB, and TFE3...TFEB / TFE3 is a key protein in the autophagy process, and TFEB / TFE3-mediated autophagy plays a crucial role in inhibiting the activation of the NLRP3 inflammasome. Activation of TFEB / TFE3 can simultaneously improve autophagy defects and NLRP3 inflammasome-mediated neuroinflammation, thus the development of novel TFEB / TFE3 activators is of great significance. The present invention aims to address the shortcomings of existing technologies, such as unclear autophagy activation mechanisms and singular anti-inflammatory mechanisms, by providing a new application of geraniol in the prevention and treatment of Alzheimer's disease (AD). The technical solution adopted in this invention is as follows: the mechanism of geraniol or its pharmaceutically acceptable salt in the preparation of drugs for the prevention and treatment of Alzheimer's disease is characterized by promoting the specific dephosphorylation of TFEB at Ser142 and Ser211 sites, thereby promoting TFEB nuclear translocation. Geraniol can also promote TFE3 nuclear translocation and effectively clear the NLRP3 inflammasome, forming a synergistic mechanism of autophagy activation and anti-inflammatory effects. This invention discloses a pharmaceutical composition for the prevention and treatment of Alzheimer's disease (AD), comprising an effective amount of geraniol (5,7,3'-trihydroxy-4'-methoxyflavone). In this embodiment, the composition is administered to a subject at a dose ranging from 17.5 mg of geraniol / kg subject / day to 65 mg of geraniol / kg subject / day. In this embodiment, the therapeutically effective amount of geraniol is administered orally. In this embodiment, the oral administration formulation is selected from tablets, capsules, granules, oral liquids, or suspensions. In this embodiment, the effective amount of geraniol is used to activate autophagy via the autolysosomal pathway mediated by promoting the dephosphorylation of at least one of transcription factor EB (TFEB) and transcription factor E3 (TFE3). In this embodiment, the autophagy activated by the autolysosomal pathway reduces the levels of amyloid precursor protein (APP) and its C-terminal fragments (CTFs) via the β-cleavage pathway. In this embodiment, the autophagy activated by the autolysosomal pathway inhibits the activation of the NLRP3 inflammasome and reduces one or more inflammatory factors, including IL-1β or interleukin-18 (IL-18). In this embodiment, the dephosphorylation of at least one of TFEB and TFE3 occurs at one or more sites, including Ser142 and Ser211 sites. In this embodiment, the effective amount of geraniol increases...LC3-II protein content. In this embodiment, the effective amount of geraniol reduces the SQSTM1 / p62 protein content. In this embodiment, the effective amount of geraniol is taken once daily. In this embodiment, the effective amount of geraniol is taken as a single dose. In this embodiment, the effective amount of geraniol further comprises one or more pharmaceutically acceptable carriers or excipients. This invention discloses the use of geraniol or a pharmaceutically acceptable derivative thereof in the preparation of a medicament for alleviating, reducing, preventing, or delaying Alzheimer's disease (AD) in an individual. In this embodiment, the medicament is administered to a subject at a dose ranging from 17.5 mg of geraniol / kg subject / day to 65 mg of geraniol / kg subject / day. In this embodiment, the pharmaceutical formulation is an oral administration formulation. In this embodiment, the oral administration formulation is selected from tablets, capsules, granules, oral liquids, or suspensions. In this embodiment, the geraniol activates autophagy via an autolysosomal pathway mediated by promoting the dephosphorylation of at least one of TFEB and TFE3. In this embodiment, the autophagy activated by the autolysosomal pathway reduces the levels of APP and its β-cleavage pathway CTFs. In this embodiment, the autophagy activated by the autolysosomal pathway inhibits the activation of the NLRP3 HK 30136967 A 4 inflammasome and reduces one or more inflammatory factors, including IL-1β or IL-18. In this embodiment, dephosphorylation of at least one of TFEB and TFE3 occurs at one or more sites, including Ser142 and Ser211 sites. In this embodiment, the drug increases LC3-II protein levels. In this embodiment, the drug reduces SQSTM1 / p62 protein levels. In this embodiment, the drug is administered once daily. In this embodiment, the drug is administered in a single dose. In this embodiment, the drug further comprises one or more pharmaceutically acceptable carriers or excipients. This application has the following beneficial effects: Compared with the prior art, this application has the following significant advantages: 1. By specifically regulating the phosphorylation state of TFEB, more precise target control is achieved than traditional autophagy activators. 2. The synergistic effect of the dual mechanisms produces a synergistic effect beyond single-target treatment, showing a more significant improvement in pathogenesis at the same dose. 3. The natural compound source ensures good safety and biocompatibility. 4. Animal experimental data show that significant efficacy can be obtained at a dose of 17.5–65 mg / kg. The chemical structural formula of the geraniol is as follows: The chemical structure of geraniol is...5,7,3'-Trihydroxy-4'-methoxyflavonoid, molecular formula C16H12O6, CAS number: 520-34-3. A first aspect of this invention provides a mechanism by which geraniol activates TFEB / TFE3-mediated autophagy-lysosome action. Specifically, geraniol can promote the dephosphorylation of TFEB at specific sites, including p-TFEB Ser142 and p-TFEB Ser211, thereby promoting the nuclear transport of endogenous TFEB. Simultaneously, geraniol can promote TFE3 nuclear translocation, activating the autophagy process. Further, geraniol, through the above mechanism, increases the expression levels of autophagy marker proteins LC3-II and Atg-7, and the lysosomal-associated protein LAMP1, enhancing autophagic flux and lysosomal activity and biosynthetic capacity, effectively promoting the degradation of APP and its CTFs. A second aspect of this invention provides a mechanism by which geraniol further degrades the NLRP3 inflammasome by activating TFEB / TFE3. This mechanism allows geraniol to exert a significant anti-inflammatory effect while activating autophagy, effectively protecting neurons from inflammatory damage. Specifically, geraniol reduces the cleavage of caspase-1 into activated caspase-1, inhibits the activation of pro-inflammatory precursors pre-IL-1β and pre-IL-18, and ultimately reduces the production of biologically active pro-inflammatory factors IL-1β and IL-18. A third aspect of this invention discloses that the effective dosage range of geraniol in animal experiments is 17.5–65 mg / kg / day, with the low-dose treatment group receiving 17.5–32.5 mg / kg / day and the high-dose treatment group receiving 35–65 mg / kg / day. Furthermore, when converting the animal experimental dose of geraniol to the human dose, the body surface area (BSA) normalization method is used for dose conversion. The correction factor (Km) is estimated by dividing the average weight (kg) of the species by its body surface area (m2). The conversion formula is as follows: HED: Human Equivalent Dose (HED, mg / kg); D Mouse: Dose used in animal experiments (mg / kg); Km, Mouse: Km value of mice (3); Km, Human: Km value of humans (37). Therefore, the animal experimental dose is 17.5–65 mg / kg / day, which is converted to a human equivalent dose of 1.42–5.27 mg / kg / day according to the above formula. If calculated based on a 60 kg adult, the effective dosage range of geraniol HK 30136967 A 6 in humans is 85.14–316.22 mg / kg / day.mg / day. Further, the geraniol can be prepared into the following oral formulations, including but not limited to: (1) tablets: geraniol mixed with pharmaceutical excipients (e.g., geraniol: microcrystalline cellulose: magnesium stearate in a weight ratio of 20-40%: 55-78%: 1-2%), granulated and compressed into tablets; (2) capsules: geraniol and suitable excipients filled into hard capsule shells; (3) oral solutions: geraniol dissolved or suspended in a solvent; (4) granules: geraniol and excipients prepared into granular formulations. Throughout the specification, a pharmaceutically acceptable salt of the above-mentioned compound refers to a molecule having the same core structure as the original compound and, after hydrolysis or other metabolic processes in vivo, capable of generating a molecule with the same or similar pharmacological effects as the original compound, thereby achieving the same or similar therapeutic effects. These pharmaceutical salts can usually be prepared from the parent compound using conventional chemical methods. Generally, pharmaceutical salts are obtained by reacting the free base of a compound with an acid in water, an organic solvent, or a mixture of both. Alternatively, non-aqueous media such as diethyl ether, ethyl acetate, ethanol, isopropanol, or acetonitrile can be used for the reaction. Furthermore, the term "effective amount" or "therapeutic effective amount" refers to the lowest dose of the compound described in this invention sufficient to achieve its intended use (including but not limited to disease treatment, daily health care, etc.). This dose may be adjusted based on various factors, such as the intended application scenario (in vitro or in vivo), the characteristics of the subject (e.g., weight, age), the severity of the disease and symptoms, and the route of administration. These factors can be easily determined by those skilled in the art. Specific doses will be adjusted based on several factors, including the specific compound selected, the dosing regimen, whether it is used in combination with other compounds, the timing of administration, the tissue of administration, and the physical delivery system used. Additionally, the term "excipient" refers to an inert component used in a pharmaceutical preparation, primarily to ensure the safety, stability, and functionality of the pharmaceutical composition. Furthermore, excipients can also help subjects more effectively accept the drug by regulating the dissolution rate of the active ingredient or promoting its absorption. These pharmaceutical excipients can be inert fillers or provide specific functions, such as maintaining the overall pH of the composition or preventing the degradation of the active ingredient. Common types of excipients include binders, suspending agents, emulsifiers, diluents, fillers, granulators, adhesives, disintegrants, lubricants, anti-adhesion agents, flow aids, wetting agents, gelling agents, absorption delay agents, dissolution inhibitors, enhancers, adsorbents, buffers, chelating agents, preservatives, colorants, flavoring agents, and sweeteners. These excipients can be used alone or in combination to meet the needs of different pharmaceutical formulations. Furthermore, the pharmaceutical compositions of the present invention can be prepared by various methods familiar to those skilled in the art. These methods include, but are not limited to, conventional mixing, dissolving, granulation, emulsification, and other methods.Processes such as grinding, encapsulation, embedding, or freeze-drying are employed. These methods can be flexibly selected according to specific needs to ensure the quality and stability of the pharmaceutical composition. The dosage range of diosmetin mentioned above is based on animal experimental results, and the dosage range for humans is based on a body surface area conversion formula. The dosage for human clinical application can be determined through further clinical trials. In addition to disclosing the use of diosmetin or its pharmaceutically acceptable derivatives in the preparation of medicaments for the sole purpose of alleviating, reducing, preventing, or delaying Alzheimer's disease (AD) in an individual, this invention also covers its combined use with other active ingredients or adjuvant compositions. These other ingredients include, but are not limited to, pharmacologically acceptable compounds, plant extracts, antioxidants, neuroprotective agents, anti-inflammatory agents, cholinesterase inhibitors, NMDA receptor antagonists, microcapsule carriers, or liposome compositions. The compositions of this invention can exhibit synergistic or additive effects to improve pathogenesis, inhibit β-amyloid protein aggregation, reduce neuroinflammatory responses, promote autophagy, or enhance mitochondrial activity. The pharmaceutical compositions of the present invention can be administered in various forms, including but not limited to intravenous injection, mucosal administration, oral (solid and liquid formulations), inhalation, ocular, rectal, topical, or parenteral (e.g., infusion, injection, implantation, subcutaneous, intravenous, intra-arterial, intramuscular) administration. These pharmaceutical compositions can also be designed as controlled-release or delayed-release dosage forms, such as liposomes or microspheres. Examples of solid oral formulations include powders, capsules, soft capsules, and tablets. Liquid formulations for oral or mucosal administration can be suspensions, emulsions, elixirs, and solutions. Examples of topical formulations include emulsions, gels, ointments, creams, drops, or serum preparations. For parenteral administration, formulations can be solutions for injection, dry formulations soluble or suspended in a pharmaceutically acceptable carrier, suspensions for injection, and emulsions for injection. Other suitable formulations include eye drops and other ophthalmic preparations, aerosols (such as nasal sprays or inhalers), liquid dosage forms suitable for parenteral administration, suppositories, and tablets. The above and other objects and features of the invention will become apparent from the following description of the invention in conjunction with the accompanying drawings. Data in the drawings are expressed as mean ± standard deviation, with statistical significance criteria as: *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Figure 1 shows that in the MTT cell viability assay, N2a cells treated with geraniol for 12 hours showed no significant toxicity at a high concentration of 200 μM. Figure 2A shows that in the immunofluorescence assay, geraniol dose-dependently promoted TFEB transport to the nucleus in HeLa cells stably expressing 3×Flag-TFEB. Figure 2B shows that in the immunofluorescence assay, geraniol in stably expressing...Quantitative analysis results of dose-dependent promotion of TFEB nuclear transport in HeLa cells using 3×Flag-TFEB. Figure 2C shows the results of Western blot (WB) assay, further confirming that geraniol promotes TFEB nuclear transport in BV2 cells after nucleocytoplasmic separation. Figure 2D shows the results of immunofluorescence assay, showing that geraniol promotes endogenous TFEB / TFE3 nuclear transport in BV2 cells in a dose-dependent manner. Figure 2E shows the results of immunofluorescence assay, showing the results of quantitative analysis of geraniol promoting endogenous TFE3 nuclear transport in BV2 cells. Figure 2F shows the results of quantitative analysis of geraniol promoting endogenous TFEB nuclear transport in BV2 cells in an immunofluorescence assay. Figure 2G shows the results of WB assay, further confirming that geraniol promotes TFEB / TFE3 nuclear transport in HeLa cells after separation of cytoplasm and nucleus. Figure 3A shows that in Western blotting (WB) experiments, 24 hours of geraniol treatment was the optimal time for TFEB dephosphorylation in HeLa cells stably expressing 3×Flag-TFEB. Figure 3B shows the quantitative analysis results of LC3-II protein levels in HeLa cells stably expressing 3×Flag-TFEB after geraniol treatment. Figure 3C shows the quantitative analysis results of the p-TFEB Ser142 ratio in HeLa cells stably expressing 3×Flag-TFEB after geraniol treatment. Figure 3D shows that in Western blotting (WB) experiments, 25 μM of geraniol was the optimal concentration for TFEB dephosphorylation in HeLa cells stably expressing 3×Flag-TFEB. Figure 3E shows the quantitative analysis results of LC3-II protein levels in HeLa cells stably expressing 3×Flag-TFEB after geraniol treatment. Figure 3F shows the quantitative analysis results of geraniol-induced p-TFEB Ser211 dephosphorylation. Figure 3G shows the quantitative analysis results of geraniol-induced p-TFEB Ser142 dephosphorylation. Figure 4A shows the changes in soluble LC3-II protein levels in N2a cells after geraniol treatment in Western blot (WB) assays. Figure 4B shows the quantitative analysis results of soluble LC3-II protein levels in N2a cells after geraniol treatment. Figure 4C shows the changes in insoluble SQSTM1 / p62 protein levels in N2a cells after geraniol treatment in Western blot (WB) assays. Figure 4D shows the insoluble SQSTM1 / p62 protein levels in N2a cells after geraniol treatment.The quantitative analysis results are shown in Figure 4E, which shows the effect of different doses of geraniol on the expression of LC3-II and LAMP1 proteins in the Western blot (WB) assay, with Torin1 as a positive control. Figure 4F shows the quantitative analysis results of LAMP1 protein levels in N2a cells after geraniol treatment. Figure 4G shows the quantitative analysis results of LC3-II protein levels in N2a cells after geraniol treatment. Figure 5 shows the fluorescence intensity changes of N2a cells after treatment with different concentrations of geraniol for 24 hours and then with the lysosomal red fluorescent probe DND-99 for 1 hour in the flow cytometry fluorescence intensity assay. Figure 6A shows the fluorescence imaging results of N2a cells transfected with GFP-RFP-LC3 plasmid for 24 hours and then treated with geraniol for 24 hours. Red spots represent degraded autolysosomes, and yellow spots represent autophagosomes, with Torin1 as a positive control and chloroquine as a negative control. Figure 6B shows the statistical analysis results of the number of degraded autolysosomes and autophagosomes in each cell. Figure 6C shows the effect of geraniol on the expression of LC3-II and SQSTM1 / p62 proteins in N2a cells under the conditions of adding lysosomal inhibitors chloroquine and bafloxacin A1 in the Western blot assay. Figure 6D shows the quantitative analysis results of the effect of geraniol on the LC3-II protein level in N2a cells. Figure 6E shows the quantitative analysis results of the effect of geraniol on the SQSTM1 / p62 protein level in N2a cells. Figure 7A shows the regulatory effect of geraniol on APP and CTFs in 7PA2 cells detected by Western blot analysis; geraniol dose-dependently reduced the levels of APP and CTFs. Figure 7B shows the quantitative analysis results of LAMP1 protein level in 7PA2 cells after geraniol treatment. Figure 7C shows the quantitative analysis results of APP protein level in 7PA2 cells after geraniol treatment. Figure 7D shows the quantitative analysis results of CTF protein levels in 7PA2 cells after geraniol treatment. Figure 8A shows the Western blotting (WB) detection of the regulatory effect of geraniol on APP and CTFs in Atg7 knockdown 7PA2 cells; geraniol failed to effectively reduce APP and CTF levels. Figure 8B shows the quantitative analysis results of APP protein levels in Atg7 knockdown 7PA2 cells after geraniol treatment. Figure 8C shows the quantitative analysis results of CTF protein levels in Atg7 knockdown 7PA2 cells after geraniol treatment. Figure 9A shows the WB detection results of geraniol in TFEB knockdown cells.The regulatory effect of geraniol on CTFs in 7PA2 cells: Geraniol significantly inhibited the degradation of APP and CTFs. Figure 9B shows the quantitative analysis results of APP protein levels in TFEB-knocked 7PA2 cells after geraniol treatment. Figure 9C shows the quantitative analysis results of CTF protein levels in TFEB-knocked 7PA2 cells after geraniol treatment. HK 30136967 A 11 Figure 10A shows the Western blotting analysis of the regulatory effect of geraniol on CTFs in TFE3-knocked 7PA2 cells, showing that geraniol significantly inhibited the degradation of APP and CTFs. Figure 10B shows the quantitative analysis results of APP protein levels in TFE3-knocked 7PA2 cells after geraniol treatment. Figure 10C shows the quantitative analysis results of CTF protein levels in TFE3-knocked 7PA2 cells after geraniol treatment. Figure 11A shows the regulatory effect of geraniol on CTFs in TFEB / TFE3 double-knockdown 7PA2 cells as detected by Western blotting. Geraniol significantly inhibited the degradation of APP and CTFs. Figure 11B shows the quantitative analysis results of APP protein levels in TFEB / TFE3 double-knockdown 7PA2 cells after geraniol treatment. Figure 11C shows the quantitative analysis results of CTF protein levels in TFEB / TFE3 double-knockdown 7PA2 cells after geraniol treatment. Figure 12A shows the regulatory effect of geraniol on inflammasome components ASC, LC3-II, IL-1β, activated caspase-1, and NLRP3 after administration in an LPS co-ATP induced IMG cell inflammation model, detected by Western blotting. Figure 12B shows the quantitative analysis results of NLRP3 protein levels in inflammation-induced IMG cells after geraniol treatment. Figure 12C shows the quantitative analysis results of IL-18 protein levels in inflammation-induced IMG cells after geraniol treatment. Figure 12D shows the quantitative analysis results of LC3-II protein levels in inflammation-induced IMG cells after geraniol treatment. Figure 12E shows the quantitative analysis results of ASC protein levels in inflammation-induced IMG cells after geraniol treatment. Figure 12F shows the quantitative analysis results of activated IL-1β protein levels in inflammation-induced IMG cells after geraniol treatment. Figure 12G shows the quantitative analysis results of pre-IL-1β protein levels in inflammation-induced IMG cells after geraniol treatment. Figure 12H shows the quantitative analysis results of activated IL-18 protein levels in inflammation-induced IMG cells after geraniol treatment. Figure 13 shows...In an LPS-ATP-induced IMG cell inflammation model, the quantitative results of caspase-1 activity regulation after geraniol administration were detected by ELISA kit. Figure 14A shows the regulatory effects of geraniol administration on inflammasome proteins ASC, LC3-II, IL-1β, activated caspase-1, and NLRP3 in an IMG cell inflammation model induced by LPS-ATP and supplemented with the autophagy inhibitor chloroquine, as detected by Western blotting. Figure 14B shows the quantitative analysis results of caspase-protoplasm-1 protein levels in IMG cells after geraniol treatment and chloroquine supplementation. Figure 14C shows the quantitative analysis results of activated caspase-1 protein levels in IMG cells after geraniol treatment and chloroquine supplementation. Figure 14D shows the quantitative analysis results of IL-1β protein levels in IMG cells after geraniol treatment and chloroquine supplementation. Figure 14E shows the quantitative analysis results of ASC protein levels in IMG cells after geraniol treatment and chloroquine supplementation. Figure 14F shows the quantitative analysis results of NLRP3 protein levels in IMG cells after inflammation-induced by geraniol treatment and the addition of chloroquine. Figure 15A shows the regulatory effects of geraniol administration on inflammasome components IL-1β and IL-18 after an IMG cell inflammation model induced by LPS co-ATP and TFEB knockdown, detected by Western blotting. Figure 15B shows the quantitative analysis results of IL-1β protein levels in IMG cells after inflammation-induced by geraniol treatment and TFEB knockdown. Figure 15C shows the quantitative analysis results of IL-18 protein levels in IMG cells after inflammation-induced by geraniol treatment and TFEB knockdown. Figure 15D shows the regulatory effects of geraniol administration on inflammasome components IL-1β and IL-18 after an IMG cell inflammation model induced by LPS co-ATP and TFEB / TFE3 knockdown, detected by Western blotting. Figure 16 shows the weight changes of mice in the C57BL6 wild-type group (WT), 5xFAD model group (Veh), low-dose treatment group (Dio-LD, 25 mg / kg), high-dose treatment group (Dio-HD, 50 mg / kg), and tablet group (TA, 50 mg / kg) after 6 months of gavage administration of geraniol. Figure 17A shows the movement trajectory of mice in the new object recognition experiment. Figure 17B shows the quantitative analysis results of the total interaction time of mice in the new object recognition experiment after geraniol treatment. Figure 17C shows the quantitative analysis results of the discrimination index of mice in the new object recognition experiment after geraniol treatment. Figure 18A shows...In the Morris water maze test, the movement trajectories of mice in the C57BL6 wild-type group (WT), 5xFAD model group (Veh), low-dose treatment group (Dio-LD, 25 mg / kg), high-dose treatment group (Dio-HD, 50 mg / kg), and tablet group (TA, 50 mg / kg) were analyzed. Figure 18B shows the quantitative analysis results of the distance traveled by mice in the water maze test after geraniol treatment. Figure 18C shows the quantitative analysis results of the time spent in the target quadrant of mice in the water maze test after geraniol treatment. Figure 19A shows the WB detection results of hippocampal tissue of 5×FAD mice after 6 months of geraniol gavage treatment, and the regulatory effects of geraniol administration on TFEB dephosphorylation level, autophagy-related markers LC3-II and SQSTM1 / p62, and lysosomal proteins CTSD, LAMP1, and CTSB were determined. Figure 19B shows the quantitative analysis results of TFEB protein levels in the hippocampus of 5×FAD mice after gavage treatment with geraniol. Figure 19C shows the quantitative analysis results of p-TFEB Ser142 protein levels in the hippocampus of 5×FAD mice after gavage treatment with geraniol. Figure 19D shows the quantitative analysis results of LC3-II protein levels in the hippocampus of 5×FAD mice after gavage treatment with geraniol. Figure 19E shows the quantitative analysis results of SQSTM1 / p62 protein levels in the hippocampus of 5×FAD mice after gavage treatment with geraniol. Figure 19F shows the quantitative analysis results of CTSB protein levels in the hippocampus of 5×FAD mice after gavage treatment with geraniol. Figure 19G shows the quantitative analysis results of CTSD protein levels in the hippocampus of 5×FAD mice after gavage treatment with geraniol. Figure 19H shows the quantitative analysis results of LAMP1 protein levels in the hippocampus of 5×FAD mice after gavage treatment with geraniol. Figure 20A shows the Western blot (WB) results of hippocampus tissue from 5×FAD mice after 6 months of gavage treatment with geraniol, determining the regulatory effect of geraniol administration on autophagy-lysosomal degradation substrates APP and CTFs. Figure 20B shows the quantitative analysis results of APP protein levels in the hippocampus of 5×FAD mice after gavage treatment with geraniol. Figure 20C shows the quantitative analysis results of CTF protein levels in the hippocampus of 5×FAD mice after gavage treatment with geraniol. Figure 21 shows the quantitative results of Aβ40 regulatory levels in the hippocampus of 5×FAD mice after 6 months of gavage treatment with geraniol, detected using an Aβ40 ELISA kit. Figure 22A shows the results of gavage treatment with geraniol.Immunofluorescence staining results of hippocampal tissue from 5×FAD mice 6 months later were obtained to determine the regulatory effect of geraniol administration on the 4G8 integrated density / percentage area. Figure 22B shows the quantitative analysis results of the 4G8 integrated density in the hippocampal tissue of 5×FAD mice after geraniol gavage treatment. Figure 22C shows the quantitative analysis results of the 4G8 percentage area in the hippocampal tissue of 5×FAD mice after geraniol gavage treatment. Figure 23A shows the immunofluorescence staining results of hippocampal tissue from 5×FAD mice 6 months after geraniol gavage treatment to determine the regulatory effect of geraniol administration on the 6E10 integrated density / percentage area. Figure 23B shows the quantitative analysis results of the 6E10 percentage area in the hippocampal tissue of 5×FAD mice after geraniol gavage treatment. Figure 23C shows the quantitative analysis results of the 6E10 integrated density in the hippocampal tissue of 5×FAD mice after geraniol gavage treatment. Figure 24A shows the co-staining immunofluorescence staining results of hippocampal tissue from 5×FAD mice after 6 months of gavage treatment with geraniol, determining the regulatory effect of geraniol on NLRP3 and ASC. Figure 24B shows the quantitative analysis results of the percentage area of ​​ASC in hippocampal tissue of 5×FAD mice after gavage treatment with geraniol. Figure 24C shows the quantitative analysis results of the percentage area of ​​NLRP3 in hippocampal tissue of 5×FAD mice after gavage treatment with geraniol. Figure 24D shows the quantitative analysis results of the integrated density of ASC in hippocampal tissue of 5×FAD mice after gavage treatment with geraniol. Figure 24E shows the quantitative analysis results of the integrated density of NLRP3 in hippocampal tissue of 5×FAD mice after gavage treatment with geraniol. Figure 24F shows the quantitative analysis results of the percentage area of ​​ASC-NLRP3 in hippocampal tissue of 5×FAD mice after gavage treatment with geraniol. Figure 25A shows the immunofluorescence staining results of IBA1 and 4G8 in the hippocampus of 5×FAD mice after 6 months of gavage treatment with geraniol, determining the regulatory effect of geraniol on IBA1. Figure 25B shows the immunofluorescence staining results of colocalization of IBA1 and 4G8 in the hippocampus of 5×FAD mice after gavage treatment with geraniol. Figure 25C shows the quantitative analysis results of the integrated density of IBA1 in the hippocampus of 5×FAD mice after gavage treatment with geraniol. Figure 26A shows the immunofluorescence staining results of GFAP and 4G8 in the hippocampus of 5×FAD mice after 6 months of gavage treatment with geraniol, determining the regulatory effect of geraniol on GFAP. Figure 26B shows the GFAP and 4G8 in the hippocampus of 5×FAD mice after gavage treatment with geraniol.Figure 26C shows the quantitative analysis results of GFAP integrated density in the hippocampus of 5×FAD mice after gavage treatment with geraniol. Figure 27A shows the results of double immunofluorescence staining of hippocampus tissue of 5×FAD mice after 6 months of gavage treatment with geraniol, determining the regulatory effect of geraniol on LAMP1 and ASC. Figure 27B shows the quantitative analysis results of the percentage area of ​​ASC-LAMP1 colocalization in hippocampus tissue of 5×FAD mice after gavage treatment with geraniol. Figure 27C shows the quantitative analysis results of the percentage area of ​​ASC in hippocampus tissue of 5×FAD mice after gavage treatment with geraniol. Figure 27D shows the quantitative analysis results of the percentage area of ​​LAMP1 in hippocampus tissue of 5×FAD mice after gavage treatment with geraniol. Figure 27E shows the quantitative analysis results of the integrated density of ASC in hippocampus tissue of 5×FAD mice after gavage treatment with geraniol. Figure 27F shows the quantitative analysis results of LAMP1 integrated density in the hippocampus of 5×FAD mice after gavage treatment with geraniol. Figure 28A shows the results of double immunofluorescence staining of hippocampus tissue from 5×FAD mice 6 months after gavage treatment with geraniol, determining the regulatory effect of geraniol administration on CTSD and ASC. Figure 28B shows the quantitative analysis results of ASC integrated density in the hippocampus of 5×FAD mice after gavage treatment with geraniol. Figure 28C shows the quantitative analysis results of the percentage area of ​​ASC in the hippocampus of 5×FAD mice after gavage treatment with geraniol. Figure 28D shows the quantitative analysis results of CTSD integrated density in the hippocampus of 5×FAD mice after gavage treatment with geraniol. Figure 28E shows the quantitative analysis results of the percentage area of ​​CTSD in the hippocampus of 5×FAD mice after gavage treatment with geraniol. Figure 28F shows the quantitative analysis results of the percentage area of ​​ASC-CTSD colocalization in the hippocampus of 5×FAD mice after gavage treatment with geraniol. Figure 29A shows the results of double immunofluorescence staining of hippocampus tissue from 5×FAD mice 6 months after gavage treatment with geraniol, determining the regulatory effect of geraniol on SQSTM1 / p62 and ASC. Figure 29B shows the quantitative analysis results of the integrated density of ASC in the hippocampus of 5×FAD mice after gavage treatment with geraniol. Figure 29C shows the quantitative analysis results of the percentage area of ​​ASC in the hippocampus of 5×FAD mice after gavage treatment with geraniol. Figure 29D shows the quantitative analysis results of the integrated density of SQSTM1 / p62 in the hippocampus of 5×FAD mice after gavage treatment with geraniol.Figure 29E shows the quantitative analysis results of the percentage area of ​​SQSTM1 / p62 in the hippocampus of 5× FAD mice after gavage treatment with geraniol. Figure 29F shows the quantitative analysis results of the percentage area of ​​ASC-SQSTM1 / p62 colocalization in the hippocampus of 5× FAD mice after gavage treatment with geraniol. Figure 30A shows the results of double immunofluorescence staining of hippocampus tissue from 5× FAD mice 6 months after gavage treatment with geraniol, determining the regulatory effect of geraniol on IL-1β. Figure 30B shows the quantitative analysis results of the percentage area of ​​IL-1β in the hippocampus of 5× FAD mice after gavage treatment with geraniol. Figure 30C shows the quantitative analysis results of the integrated density of IL-1β in the hippocampus of 5× FAD mice after gavage treatment with geraniol. Figure 31A shows the Western blot (WB) results of hippocampal tissue from 5×FAD mice after 6 months of gavage treatment with geraniol, determining the regulatory effects of geraniol on 6E10 and SQSTM1 / p62 in soluble and insoluble proteins. Figure 31B shows the quantitative analysis results of soluble 6E10 protein in hippocampal tissue from 5×FAD mice after gavage treatment with geraniol. Figure 31C shows the quantitative analysis results of insoluble 6E10 protein in hippocampal tissue from 5×FAD mice after gavage treatment with geraniol. Figure 31D shows the quantitative analysis results of soluble SQSTM1 / p62 protein in hippocampal tissue from 5×FAD mice after gavage treatment with geraniol. Figure 31E shows the quantitative analysis results of insoluble SQSTM1 / p62 protein in hippocampal tissue from 5×FAD mice after gavage treatment with geraniol. Figure 32A shows the dot blot analysis results of hippocampal tissue from 5×FAD mice after 6 months of gavage treatment with geraniol, determining the regulatory effect of geraniol on A11 oligopeptide protein in mouse hippocampal tissue. Figure 32B shows the quantitative analysis results of A11 oligopeptide protein in hippocampal tissue of 5×FAD mice after gavage treatment with geraniol. Figure 33 schematically illustrates the mechanism by which geraniol alleviates the pathogenesis of Alzheimer's disease in mice by activating at least one autolysosomal pathway mediated by TFEB / 3 and inhibiting the activation of NLRP3 inflammasome. Detailed Description of the Embodiments HK 30136967 A 18 The detailed description and technical content of this application are explained below with reference to the accompanying drawings. However, the drawings are provided for reference and illustration only and are not intended to limit the application. This invention reveals a novel mechanism by which geraniol exerts its anti-Alzheimer's disease effect by activating the autolysosomal pathway mediated by TFEB / TFE3 and inhibiting the activation of NLRP3 inflammasome. In vitro experimental example 1: Evaluation of geraniol cytotoxicityThe effect of geraniol on N2a cell viability was detected using the MTT assay. N2a cells were seeded into 96-well plates and cultured at 37°C in a 5% CO₂ incubator until cell confluence reached approximately 60%. Geraniol was added to each well according to the experimental design at final concentrations of 3.125, 6.25, 12.5, 25, 50, 100, and 200 μM. Incubation was continued at 37°C in a 5% CO₂ incubator for 12 hours. After incubation, 20 μL of MTT (5 mg / mL) solution was added to each well, and the cells were returned to the incubator for another 4 hours. After incubation, the culture medium was carefully aspirated from the wells, and 150 μL of dimethyl sulfoxide (DMSO) solution was added to each well, gently shaking for 10 minutes until the purple formazan crystals were completely dissolved. Cell viability was assessed by measuring the absorbance (OD₅₇₀) of each well at 570 nm using a microplate reader. The results showed that geraniol did not exhibit significant cytotoxicity within the concentration range < 100 μM (Figure 1), providing a safe concentration range for subsequent experiments. Example 2: Validation of the mechanism by which geraniol promotes TFEB / TFE3 nuclear transport 2.1 Validation in HeLa cells stably expressing 3×Flag-TFEB Immunofluorescence was used for detection. HeLa cells were seeded in six-well plates and cultured. When the cells reached approximately 60% confluence, geraniol was added at final concentrations of 6.25 μM, 12.5 μM, and 25 μM, respectively, and the cells were incubated at 37°C and 5% CO₂ for 24 hours. After incubation, the culture medium was discarded, and the cells were gently washed once with PBS. An appropriate amount of cytoplasmic lysis buffer was added, and the cells were lysed on ice for 15 minutes. Then, the cells were centrifuged at 4°C and 600×g for 15 minutes, and the supernatant was collected as the cytoplasmic fraction. The resulting cell pellet was added to nuclear lysis buffer, sonicated, and lysed on ice for 15 minutes. The cells were then centrifuged at 4°C and 1000×g for 15 minutes, and the supernatant was collected as the nuclear fraction for subsequent Western blotting (WB) sample preparation. HK 30136967 A 19 found that geraniol could promote the transport of TFEB to the nucleus in a dose-dependent manner (Figure 2A-B). This result was further confirmed by nuclear-cytoplasmic separation combined with WB analysis (Figure 2C). 2.2 Validation of Endogenous TFEB / TFE3 in BV2 Microglia BV2 cells were seeded in six-well plates and cultured until approximately 60% confluence. Geraniol was then added at final concentrations of 6.25 μM, 12.5 μM, and 25 μM, respectively, and incubated at 37°C and 5% CO₂ for 24 hours. After incubation, the culture medium was discarded, and the cells were incubated with PBS.The cells were gently washed once, then pre-chilled cytoplasmic lysis buffer was added, and the cells were lysed on ice for 15 minutes. The cells were then centrifuged at 4°C and 600×g for 15 minutes, and the supernatant was collected as the cytoplasmic fraction. The resulting precipitate was added to nuclear lysis buffer, sonicated, and lysed on ice for 15 minutes. The cells were then centrifuged at 4°C and 1000×g for 15 minutes, and the supernatant was collected as the nuclear fraction for subsequent Western blotting (WB) sample preparation. In BV2 microglia, geraniol also exhibited a dose-dependent effect in promoting endogenous TFEB / TFE3 nuclear transport (Figures 2D-F). WB analysis after nucleoplasmic separation further confirmed these findings (Figure 2G). Example 3: Determination of the optimal conditions for geraniol-induced TFEB dephosphorylation. An immunohistochemical method was used to systematically test the reaction in N2a cells at 6 time points and 3 concentration gradients. Experimental results determined that 24 hours of treatment and a concentration of 25 μM were the optimal conditions for inducing TFEB dephosphorylation (Figures 3A-E). By systematically detecting the phosphorylation status of TFEB Ser211 and Ser142 sites at different time points and concentrations, it was determined that geraniol has a dose-dependent and time-dependent TFEB dephosphorylation effect (Figures 3F-G). Example 4: Verification of Geraniol's Enhancement of Autophagy Activity 4.1 Detection of Changes in Autophagy Marker Proteins Using the autophagy activator Torin1 as a positive control, protein solubility analysis was performed: N2a cells were seeded in six-well plates and cultured until the cells reached approximately 60% confluence. Geraniol was then added at final concentrations of 6.25 μM, 12.5 μM, and 25 μM, and incubated at 37°C and 5% CO₂ for 24 hours. After incubation, the culture medium was discarded, and the sample was gently washed once with PBS. Pre-cooled soluble lysis buffer was added, and the sample was lysed on ice for 15 minutes. After centrifugation at 4°C and 600×g for 15 minutes, the supernatant was collected as the soluble fraction. The resulting precipitate was added to insoluble lysis buffer (HK 30136967 A 20), and after disruption, lysis was continued on ice for 15 minutes. The sample was then centrifuged at 4°C and 1000×g for 15 minutes, and the supernatant was collected as the insoluble fraction, which was subsequently used for Western blotting (WB) sample preparation. The experimental results showed that geraniol treatment significantly increased the content of soluble LC3-II protein, while significantly decreasing the content of insoluble SQSTM1 / p62 protein (Figures 4A-D). 4.2 Analysis of Autophagy Biosynthesis-Related Protein Expression: The results showed that geraniol dose-dependently upregulated the expression levels of autophagy marker protein LC3-II and lysosome-related protein LAMP1 (Figures 4E-G). 4.3 Lysosomal Activity DetectionUsing lysosomal red fluorescent probe DND-99 staining combined with flow cytometry analysis, N2a cells treated with different concentrations of geraniol for 24 hours showed a significant increase in lysosomal fluorescence intensity (Figure 5), indicating that geraniol can effectively enhance lysosomal activity. Example 5: Study on the mechanism of geraniol enhancing autophagy flux 5.1 Autophagy flux detection N2a cells were transfected with GFP-RFP-LC3 plasmid, with Torin1 as a positive control and chloroquine as a negative control. The results showed that the number of red fluorescent spots (autophagic lysosomes) increased significantly after geraniol treatment, confirming that geraniol can significantly promote autophagy flux (Figure 6A-B). 5.2 Autophagy mechanism confirmation experiment Western blotting analysis was performed in the presence of the autophagy inhibitor bafloxacin A1. Geraniol further increased the expression level of LC3-II, confirming that geraniol increases LC3-II expression by promoting autophagy rather than inhibiting autophagic degradation (Figure 6C-E). Example 6: Study on the Degradation Effect of Geraniol on APP and CTFs 6.1 Effect of Geraniol on APP and CTF Expression The experiment was conducted using the CHO 7PA2 cell line stably expressing a human amyloid precursor protein mutant. After treatment with different concentrations (6.25, 12.5, 25 μM) of geraniol for 24 hours, the expression levels of APP and CTFs decreased in a dose-dependent manner, indicating that geraniol could promote the degradation of APP and CTFs (Figures 7A-D). 6.2 Verification of the Role of Autophagy-Related Proteins in APP / CTF Degradation Knockdown of Atg7 using siRNA technology significantly reduced the degradation effect of geraniol on APP and CTFs (Figures 8A-C), confirming that the autophagy pathway is involved in this degradation process. 6.3 Mechanism of TFEB / TFE3 in APP / CTF Degradation Knockdown of TFEB or TFE3 using siRNA technology partially inhibited the degradation of CTFs by geraniol (Figures 9A-C, 10A-C). When both TFEB and TFE3 were knocked out simultaneously, the degradation of APP and CTFs by geraniol almost completely disappeared (Figures 11A-C), confirming that TFEB / TFE3 plays a key role in this process. Example 7: Study on the anti-inflammatory mechanism of geraniol 7.1 Detection of NLRP3 inflammasome inhibitory effect An NLRP3 inflammasome activation model of IMG cells was established using LPS co-ATP treatment. IMG cells were uniformly seeded in six-well plates and cultured until the cells reached approximately 70% confluence. Geraniol at a final concentration of 25 μM was added and incubated for 1 hour; then LPS was added and incubation continued.6 hours. After incubation, the culture medium was discarded, and equal volumes of Opti medium and ATP mixture were added. After incubation for another 30 minutes, the cell supernatant was collected. The supernatant was added to trichloroacetic acid (TCA) at a volume ratio of 1:3 and incubated overnight at 4°C to precipitate proteins. The supernatant was discarded the next day, and the precipitate was washed three times with acetone. The resulting precipitate was added to 4× loading buffer, sonicated, and heat-treated at 70°C for 5 minutes. After preparation, Western blot analysis was performed. The results showed that geraniol could dose-dependently inhibit NLRP3, degrade the expression levels of activated IL-1β, IL-18, and ASC, and dose-dependently increase LC3-II levels, indicating that geraniol clears NLRP3 inflammasome activation through autophagy (Figure 12A-H). 7.2 Caspase-1 activity detection The changes in caspase-1 activity were analyzed using ELISA. The results showed that geraniol could significantly reduce caspase-1 activity (Figure 13). 7.3 Validation of Autophagy-Dependent Anti-inflammatory Mechanism: IMG cells were uniformly seeded in six-well plates and cultured until approximately 70% confluence. Geraniol at a final concentration of 25 μM was added and incubated for 1 hour. LPS was then added, with chloroquine added at the 3rd hour of incubation. The entire LPS treatment lasted 6 hours. After treatment, the culture medium was discarded, and an equal volume of Opti medium and ATP mixture was added. Incubation was continued for another 30 minutes to promote cell response, followed by collection of the supernatant. TCA (HK 30136967 A 22) was added at a 1:3 ratio to the supernatant volume and the mixture was incubated overnight at 4°C. The supernatant was discarded the next day, and the precipitate was washed three times with acetone. The washed precipitate was added to 4× loading buffer, sonicated, and then heat-treated at 70°C for 5 minutes. The resulting sample was used for Western blotting analysis. In the presence of the autophagy inhibitor chloroquine, geraniol lost its inhibitory effect on inflammasome components such as ASC, IL-1β, activated caspase-1, IL-18, and NLRP3 (Figures 14A-F), further confirming that its anti-inflammatory effect depends on the autophagy pathway. Example 8: Functional verification of TFEB / TFE3 in the anti-inflammatory effect of geraniol. IMG cells were uniformly seeded in six-well plates and cultured until they reached 40%–50% confluence. TFEB was added, and the cells were cultured for another 48 hours to complete gene interference. After interference, geraniol at a final concentration of 25 μM was added and incubated for 1 hour, followed by LPS and incubation for another 6 hours. Chloroquine was added at the 3rd hour of treatment to inhibit autophagy. After treatment, the culture medium was discarded, and an equal volume of Opti medium and ATP mixture was added. After incubation for another 30 minutes, the supernatant was collected. The supernatant was then diluted 1:3.Pre-cooled TCA was added in a volume ratio, and the protein was precipitated overnight at 4 °C. The supernatant was discarded the next day, and the precipitate was washed three times with acetone. Finally, the washed protein precipitate was resuspended in 4× loading buffer, sonicated, and heat-treated at 70 °C for 5 minutes before use for Western blotting (WB) sample preparation. WB analysis showed that in IMG cells with TFEB knockdown, geraniol lost its inhibitory effect on inflammasome components (ASC, IL-1β, activated caspase-1, IL-18, and NLRP3) (Figures 15A-C). Simultaneous knockout of TFEB and TFE3 in BV2 microglia showed a significantly reduced ability of geraniol to degrade inflammasomes (Figure 15D), confirming the necessity of TFEB / TFE3 in the anti-inflammatory effect of geraniol. Animal Experiment Example 9: Safety Assessment of Geraniol To evaluate the long-term safety of geraniol, mice were divided into a C57BL6 wild-type group, a 5xFAD model group (Veh), a low-dose treatment group (25 mg / kg), a high-dose treatment group (50 mg / kg), and a tablet group (50 mg / kg) and administered orally for 6 consecutive months. Geraniol was added directly to 4% CMC Na in a specific ratio and then ultrasonically (or thoroughly agitated) to ensure uniform dispersion before use. The tablet group consisted of geraniol mixed with excipients (such as microcrystalline cellulose, magnesium stearate, etc.) in a specific ratio, where geraniol accounted for 20%–40% of the total weight, microcrystalline cellulose for 55%–78%, and magnesium stearate for 1%–3%. After mixing, the mixture was granulated and compressed into tablets. For use, the tablets were added to deionized water according to the dosage ratio and then ultrasonically or thoroughly agitated to ensure uniform dispersion before use. Throughout the administration period, mouse weight, physiological status, and behavioral performance were monitored regularly. The results showed no significant difference in weight changes between the control and all dosage groups (Figure 16), and no abnormal behavior or toxic reactions were observed, suggesting that geraniol has good safety and tolerability within the dosage range of 25–50 mg / kg / day. Example 10: Neuroprotective Effect of Geraniol on AD Model Mice This example aims to evaluate the effect of geraniol on the pathogenesis of 5xFAD mice. The experimental design is divided into the following two parts. 10.1 Experimental Design Mice were randomly divided into C57BL6 wild-type group, 5xFAD model group, low-dose treatment group (25 mg / kg), high-dose treatment group (50 mg / kg), and tablet group (50 mg / kg), with 14 mice in each group. Each group received corresponding treatment for 26 consecutive weeks. The model group and positive control group were given an equal volume of solvent or a known neuroprotective agent, respectively. 10.2 New Object Recognition Experiment All mice were allowed to freely adapt to the new environment for 5 minutes before the test. During the training phase,Two identical meaningless objects were placed in a behavior box, and mice explored freely for 5 minutes to confirm no preference. One hour later, a testing phase was conducted, where one object was replaced with a new object, and the mice explored again for 5 minutes. The exploration time and number of explorations for both the old and new objects were recorded. Results showed that mice in the low-dose, high-dose, and tablet treatment groups explored the new object significantly more often and for longer than the model group during the testing phase, indicating that geraniol significantly enhanced the ability to recognize new objects (Figure 17A–C) and improved the morbidity of 5xFAD mice. 10.3 Morris Water Maze Test After the new object recognition experiment, the Morris Water Maze was used to test the spatial learning and memory retention of mice in each group for 6 days. Escape latency was recorded during daily training; on day 7, the swimming distance and time spent in the target quadrant were recorded. All groups showed a decrease in escape latency with each training day, indicating improved learning ability. Compared with the model group, the escape latency was significantly shortened in the low-dose, high-dose treatment groups and the tablet group, and the swimming distance and dwell time in the target quadrant on day 7 were significantly increased, indicating that geraniol can improve the pathogenesis of 5xFAD mice (Figure 18A–C). Example 11: Regulatory effect of geraniol on protein expression in AD model mice 11.1 Detection of autophagy-lysosomal pathway-related proteins After 26 weeks of gavage administration, hippocampal tissue of mice was extracted for Western blot analysis. The results showed that geraniol could significantly enhance the expression of lysosomal biogenesis-related proteins (LAMP1, CTSD) and autophagy marker protein (LC3-II) in 5xFAD mice, while promoting TFEB dephosphorylation (reduced p-TFEB Ser142 level) (Figure 19A-H). 11.2 Verification of APP and CTF Degradation Effects: Geraniol treatment significantly reduced the levels of APP and CTF proteins in the hippocampus of 5xFAD mice in a dose-dependent manner (Figure 20A-C). This result is consistent with the in vitro experimental results, further confirming that geraniol degrades pathological proteins by promoting the autophagy-lysosomal pathway. 11.3 Aβ Level Detection: ELISA results showed that the Aβ40 level in the hippocampus of 5xFAD mice significantly decreased after geraniol administration (Figure 21), indicating its therapeutic effect in clearing amyloid protein. Example 12: Immunofluorescence Histochemical Verification 12.1 Amyloid Protein Clearance Effect: Immunofluorescence staining results showed that geraniol significantly reduced the positive signals of 4G8 (Figure 22A-C) and 6E10 (Figure 23A-C) in the brain tissue of 5xFAD mice, confirming its clearing effect on amyloid protein. 12.2 Inflammasome Inhibitory EffectDouble immunofluorescence staining showed that geraniol significantly reduced the expression of NLRP3 (green fluorescence) and ASC (red fluorescence) in the brain tissue of 5xFAD mice (Fig. 24A-F). 12.3 Glial cell activation and amyloid colocalization analysis Immunofluorescence colocalization analysis showed that geraniol enhanced the colocalization of GFAP and 4G8 (Fig. 25A-C) and Iba1 and 4G8 (Fig. 26A-C), indicating that glial cells have an enhanced ability to clear amyloid protein. 12.4 Correlation analysis of lysosomal function and inflammation Immunofluorescence results showed that geraniol upregulated the expression of lysosomal marker proteins LAMP1 and CTSD HK 30136967 A 25, while reducing ASC expression (Fig. 27A-F, Fig. 28A-F). Furthermore, the expression of autophagy substrate SQSTM1 / p62 and inflammatory cytokine IL-1β were significantly decreased, accompanied by a decrease in ASC levels (Fig. 29A-F, Fig. 30A-C). Example 13: Protein Solubility Analysis The effects of geraniol on the distribution of 6E10 and SQSTM1 / p62 proteins in the hippocampus of 5xFAD mice were detected using soluble / insoluble protein separation technology. The results showed that geraniol significantly improved protein aggregation (Fig. 31A-E), further confirming its mechanism of action in clearing pathological protein aggregates through autophagy. Example 14: Blot Analysis Blot analysis results showed that the level of A11 oligopeptide protein in the hippocampus of 5xFAD mice was significantly decreased after geraniol administration (Fig. 32A-B), indicating its therapeutic effect in clearing amyloid protein. Please refer to Figure 33, which shows that in microglia of the brain tissue of mice with Alzheimer's disease, some Aβ accumulates in vesicles and cannot be transported to lysosomes for degradation, while some Aβ is transported to lysosomes for degradation and is encapsulated in autophagosomes. As shown in Figure 33, Aβ can also enter through the NF-κB pathway. Damaged autophagosomes lead to the accumulation of Aβ-loaded autophagosomes, which not only fail to degrade toxic proteins but also cause lysosomal rupture due to decreased lysosomal membrane stability, releasing cathepsins into the cytoplasm. This endogenous signal triggers the next stage of activation: NLRP3 recruits the adaptor protein ASC, which further polymerizes to form a giant ASC, thereby triggering oligomerization of the NLRP3 inflammasome. This process induces the activation of caspase-1, which performs its protease function by cleaving the precursors pre-IL-1β and pre-IL-18 in the cytoplasm, processing them into mature secreted IL-1β and IL-18. IL-1β is primarily responsible for amplifying systemic inflammatory signals, while IL-18 is involved in inducing IFN-γ secretion and enhancing inflammatory activity.Neurotoxicity is closely related to neurotoxicity, and both contribute to the neuroinflammation described above. Referring to Figure 33, effective amounts of geraniol can effectively regulate the autolysosomal pathway mediated by transcription factors TFEB and TFE3. After TFEB / TFE3 enters the nucleus, it precisely binds to the CLEAR (Coordinated Lysosomal Expression and Regulation) sequence in the ALP gene promoter region. Activation of TFEB / TFE3 can simultaneously improve autophagy deficiency and NLRP3 inflammasome-mediated neuroinflammation. Geraniol can promote the dephosphorylation of TFEB at specific sites, including p-TFEB Ser142 and p-TFEB Ser211, thereby promoting the nuclear transport of endogenous TFEB. Simultaneously, geraniol can promote TFE3 nuclear translocation. By specifically regulating the phosphorylation state of TFEB, it achieves more precise target control than known autophagy activators. Please refer to Figure 33. Geraniol further degrades the oligomerization mechanism of the aforementioned NLRP3 inflammasome by activating TFEB / TFE3. This unexpected technical effect of degrading the oligomerization mechanism of the aforementioned NLRP3 inflammasome allows geraniol to exert a significant anti-inflammatory effect while activating autophagy, effectively protecting neurons from inflammatory damage. Specifically, geraniol effectively reduces the cleavage of caspase-1 into activated caspase-1, thereby inhibiting the activation of pro-inflammatory cytokine precursors and reducing the production of biologically active pro-inflammatory cytokines IL-1β and IL-18. The above-described embodiments are merely preferred embodiments for the purpose of fully illustrating this application, and the scope of protection of this application is not limited thereto. Equivalent substitutions or modifications made by those skilled in the art based on this application are all within the scope of protection of this application. HK 30136967 A 1 Claim 1. A pharmaceutical composition comprising an effective amount of geraniol (5,7,3'-trihydroxy-4'-methoxyflavone). 2. The pharmaceutical composition of claim 1, wherein the composition is administered to a subject at a dose of 17.5 mg of geraniol / kg subject / day to 65 mg of geraniol / kg subject / day. 3. The pharmaceutical composition of claim 1 or 2, wherein the effective amount of geraniol is administered orally. 4. The pharmaceutical composition of claim 1, wherein the oral administration is selected from tablets, capsules, granules, oral solutions, or suspensions. 5. The pharmaceutical composition of claim 1, wherein it comprises an effective amount of geraniol by promoting transcription factor EB (TFEB) and transcription...Autophagy is activated via the autolysosomal pathway mediated by the dephosphorylation of at least one of Transcription factor E3 (TFE3). 6. The pharmaceutical composition of claim 5, wherein the autophagy activated by the autolysosomal pathway reduces the levels of amyloid precursor protein (APP) and its C-terminal fragments (CTFs) via the β-cleavage pathway. 7. The pharmaceutical composition of claim 5, wherein the autophagy activated by the autolysosomal pathway inhibits the activation of the NLRP3 inflammasome and reduces one or more inflammatory factors, including IL-1β or IL-18. 8. The pharmaceutical composition of claim 5, wherein the dephosphorylation of at least one of TFEB and TFE3 occurs at one or more sites, including the Ser142 and Ser211 sites. 9. The pharmaceutical composition of claim 1, wherein the effective amount of geraniol increases LC3-II protein content. 25 10. The pharmaceutical composition of claim 1, wherein the effective amount of geraniol reduces the SQSTM1 / p62 protein content. HK 30136967 A 2 11. The pharmaceutical composition of claim 1, wherein the effective amount of geraniol is taken as a single dose. 12. The pharmaceutical composition of claim 1, wherein the effective amount of geraniol further comprises one or more pharmaceutically acceptable carriers or excipients. 13. Use of a geraniol (5,7,3'-trihydroxy-4'-methoxyflavone) or a pharmaceutically acceptable derivative thereof in the preparation of a medicament for alleviating, preventing or delaying Alzheimer's disease (AD) in an individual. 14. The use of claim 14, wherein the medicament is administered to a subject at a dose of 17.5 mg of the geraniol / kg subject / day to 65 mg of the geraniol / kg subject / day. 10 15. The use of claim 14 or 15, wherein the pharmaceutical formulation is an oral administration formulation. 16. The use according to claim 16, wherein the oral administration formulation is selected from tablets, capsules, granules, oral solutions, or suspensions. 17. The use according to claim 14, wherein the geraniol activates autophagy via an autolysosomal pathway mediated by promoting the dephosphorylation of at least one of TFEB and 15TFE3. 18. The use according to claim 18, wherein the autophagy activated by the autolysosomal pathway reduces the levels of APP and its β-cleavage pathway CTFs.19. The use of claim 18, wherein the autophagy activated by the autolysosomal pathway inhibits the activation of the NLRP3 inflammasome and reduces one or more inflammatory factors, 20. the one or more inflammatory factors including IL-1β and IL-18. 20. The use of claim 18, wherein the dephosphorylation of at least one of TFEB and TFE3 occurs at one or more sites, the one or more sites including Ser142 and Ser211 sites. 21. The use of claim 14, wherein the drug increases LC3-II protein 25 content. 22. The use of claim 14, wherein the drug reduces SQSTM1 / p62 protein content. HK 30136967 A 3 23. The use of claim 14, wherein the drug is administered in a single dose. 24. The use of claim 14, wherein the drug further comprises one or more pharmaceutically acceptable carriers or excipients. HK 30136967 A 1 Instruction Manual Attachments Figure 1 Figure 2A HK 30136967 A 2 Figure 2B Figure 2C HK 30136967 A 3 Figure 2D Figure 2E HK 30136967 A 4 Figure 2F Figure 2G HK 30136967 A 5 Figure 3A Figure 3B HK 30136967 A 6 Figure 3C Figure 3D HK 30136967 A 7 Figure 3E Figure 3F HK 30136967 A 8 Figure 3G Figure 4A HK 30136967 A 9 Figure 4B Figure 4C HK 30136967 A 10 Figure 4D Figure 4E HK 30136967 A 11 Figure 4F Figure 4G LAMP 1 / ACTB Ctrl 6.25 12.5 25 Torin1 0.0 0.5 1.0 1.5 2.0 * Dio(μM) ** ** ** HK 30136967 A 12 Figure 5 Figure 6A HK 30136967 A 13 Figure 6B Figure 6C HK 30136967 A 14 Figure 6D Figure 6E HK 30136967 A 15 Figure 7A Figure 7B HK 30136967 A 16 Figure 7C Figure 7D HK 30136967 A 17 Figure 8A Figure 8B HK 30136967 A 18 Figure 8C Figure 9A HK 30136967 A 19 Figure 9B Figure 9C HK 30136967 A 20 Figure 10A Figure 10BHK 30136967 A 21 Figure 10C Figure 11A HK 30136967 A 22 Figure 11B Figure 11C HK 30136967 A 23 Figure 12A HK 30136967 A 24 Figure 12B Figure 12C HK 30136967 A 25 Figure 12D Figure 12E HK 30136967 A 26 Figure 12F Figure 12G HK 30136967 A 27 Figure 12H Figure 13 HK 30136967 A 28 Figure 14A HK 30136967 A 29 Figure 14B Figure 14C HK 30136967 A 30 Figure 14D Figure 14E HK 30136967 A 31 Figure 14F HK 30136967 A 32 Figure 15A HK 30136967 A 33 Figure 15B Figure 15C HK 30136967 A 34 Figure 15D HK 30136967 A 35 Figure 16 Figure 17A Figure 17B HK 30136967 A 36 Figure 17C Figure 18A HK 30136967 A 37 Figure 18B Figure 18C HK 30136967 A 38 Figure 19A Figure 19B HK 30136967 A 39 Figure 19C Figure 19D HK 30136967 A 40 Figure 19E Figure 19F HK 30136967 A 41 Figure 19G Figure 19H HK 30136967 A 42 Figure 20A Figure 20B HK 30136967 A 43 Figure 20C Figure 21 HK 30136967 A 44 Figure 22A Figure 22B HK 30136967 A 45 Figure 22C Figure 23A HK 30136967 A 46 Figure 23B Figure 23C HK 30136967 A 47 Figure 24A HK 30136967 A 48 Figure 24B Figure 24C HK 30136967 A 49 Figure 24D Figure 24E HK 30136967 A 50 Figure 24F Figure 25A HK 30136967 A 51 Figure 25B Figure 25C HK 30136967 A 52 Figure 26A Figure 26B HK 30136967 A 53 Figure 26C Figure 27A HK 30136967 A 54 Figure 27B Figure 27C HK 30136967 A 55 Figure 27D Figure 27E HK 30136967 A 56 FigureFigure 27F, Figure 28A, HK 30136967 A, Figure 28B, Figure 28C, HK 30136967 A, Figure 28D, Figure 28E, HK 30136967 A, Figure 28F, Figure 29A, HK 30136967 A, Figure 29B, Figure 29C, HK 30136967 A, Figure 29D, Figure 29E, HK 30136967 A, Figure 29F, Figure 30A, HK 30136967 A, Figure 30B, Figure 30C, HK 30136967 A, Figure 31A, Figure 31B, HK 30136967 A, Figure 31C, Figure 31D, HK 30136967 A, Figure 31E, Figure 32A, HK 30136967 A, Figure 32B Figure 33 HK 30136967 A